title: Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.
abstract: Proteomic-based biomarkers are now an integral part of the drug development process. This chapter covers the role of proteomic biomarker tests as useful tools for improving preclinical research and clinical development. One medical area that has been lagging behind this process is the study of psychiatric disorders, and this is most likely due to the complexity of these diseases. The potential of incorporating biomarkers in the clinical pipeline to improve decision-making, accelerate drug development, improve translation and reduce development costs is also discussed, with a focus on psychiatric diseases like schizophrenia. This chapter will also discuss the next steps that must be taken to keep moving this process forwards.
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, CB2 3RA, Cambridge, UK.
authors.forename: Hassan
authors.initials: H
authors.lastname: Rahmoune
authors.affiliation: Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255 F/01, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.|UNICAMP's Neurobiology Center, Rua Monteiro Lobato 255, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.
authors.forename: Daniel
authors.initials: D
authors.lastname: Martins-de-Souza
authors.affiliation: Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255 F/01, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil. paulcguest@yahoo.com.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Guest
mesh_terms: D015415:Biomarkers / Q000097:blood*; D002986:Clinical Trials as Topic / Q000379:methods; D003362:Cost-Benefit Analysis; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods; D005544:Forecasting; D006801:Humans; D007118:Immunoassay / Q000379:methods; D013058:Mass Spectrometry / Q000379:methods; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy*; D000067716:Point-of-Care Testing; D040901:Proteomics / Q000379:methods*; D011619:Psychotropic Drugs / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D011619:Psychotropic Drugs
keywords: Biomarker; Clinical development; Drug discovery; Pharmaceutical company; Proteomics; Psychiatric disorders